PUBLIC-PRIVATE PARTNERSHIP IN THE IMPLEMENTATION OF INNOVATIVE PROJECTS ASSOCIATED WITH PHARMACEUTICAL DEVELOPMENTS FOR THE TREATMENT OF SOCIALLY SIGNIFICANT DISEASES

Authors

DOI:

https://doi.org/10.11603/2312-0967.2019.1.9931

Keywords:

public-private partnership, innovative drug, project, socially significant diseases

Abstract

The aim of the work. Analysis of the state and development trends of public-private partnerships (PPP) abroad in solving global problems in creating innovative drugs for the treatment of socially significant diseases, generalizing world experience of the feasibility of using certain PPP tools and developing the system of indicators to assess the effectiveness of PPP in pharmacy .

Materials and Methods. In the process of research it has used general scientific methods of cognition, in particular, a systematic approach using methods of retrospective and system-logical analysis, content analysis.

Results and Discussion. The conditions for the effective implementation of PPP projects, the most commonly used state-owned tools for PPP support in various countries, have determined. The benefits and risks of using PPP mechanisms in the implementation of innovative projects is associated with pharmaceutical developments for the treatment of socially significant diseases have analyzed. The system of indicators for evaluating the effectiveness of PPP in pharmacy in the following areas: cooperation, research activity, know-how, human capital, finance, has proposed.

Conclusions. The development of PPP to enhance the creation of innovative drugs for the treatment of socially significant diseases (hepatitis, HIV, oncopathology, antibiotic resistance, tuberculosis, etc.) contributes to the unification of unique innovative resources and the distribution of risks associated with a high degree of uncertainty of innovative activity results; increasing the innovative potential of the pharmaceutical industry in the process of joint activity organizations; allows to expand financial resources needed to reform the health care system, optimizes budget expenditures, increases the efficiency of investments in health care, which ultimately contributes to improving the quality of medical and pharmaceutical services.

Author Biographies

O. V. Litvinova, National University of Pharmacy

Doctor of Sciences (in Pharmacy), associate professor of the management and economics of enterprise department

O. V. Posilkina, National University of Pharmacy

Doctor of Sciences (in Pharmacy), professor, Head of the management and economics of enterprise department

References

Mamedyarov ZA. Public innovation policy in the pharmaceutical industry: the cases of the EU and USA. MIR (Modernizatsiya. Innovatsiya. Razvitiye). 2017;8(1): 105-114. DOI: https://doi.org/10.18184/2079-4665.2017.8.1.105-114. Russian.

Varnavsky VG. Public-private partnership in healthcare: international experience. Uprav zdravookr. 2010;1: 9-16. Russian.

Dmitrik E. Public-private partnership in healthcare. International experience. Yezened apteka. 2017;1104(33). Available from: https://www.apteka.ua/article/423444. Russian.

Kotvitska АА, Kostiuk VH. Investigation of normative legal regulation of import-substituting production of medicines in Ukraine. Upravl, ekonomika ta zapezp yakosti v farmatsii. 2016;1:44-8. DOI: https://doi.org/10.24959/uekj.16.6. Ukrainian.

Pharmacy of the 21st century: Trends and prospects: Materials of VIII Congress of Pharmacists of Ukraine. Kharkiv: NFaU; 2016. Ukrainian

Mishra P, Florian J, Peter J, Vainorius M, Fried MW, Nelson DR, Birnkrant D. Public-private partnership: targeting real-world data for hepatitis c direct-acting antivirals. Gastroenterology. 2017; 153(3): 626-31. DOI: 10.1053/j.gastro.2017.07.025.

Shrivastava R, Fonjungo PN, Kebede Y, Bhimaraj R, Zavahir S, Mwangi C, Gadde R, Alexander H, Riley PL, Kim A, Nkengasong JN. Role of public-private partnerships in achieving UNAIDS HIV treatment targets. BMC Health Serv Res. 2019;19(1): 46. DOI: 10.1186/s12913-018-3744-z.

Dercle L, Connors DE, Tang Y, Adam SJ, Gönen M, Hilden P, Karovic S et al. Vol-PACT: A Foundation for the NIH public-private partnership that supports sharing of clinical trial data for the development of improved imaging biomarkers in oncology. JCO Clin Cancer Inform. 2018;(2): 1-12. DOI: 10.1200/CCI.17.00137.

Ramsey BW, Nepom GT, Lonial S. Academic, foundation, and industry collaboration in finding new therapies. N Engl J Med. 2017;376(18): 1762-9. DOI: 10.1056/NEJMra1612575.

Abbasi J. Public-private partnership speeds investigator access to cancer Drugs. JAMA. 2017;317(8): 797. DOI: 10.1001/jama.2017.1089.

Shelby PW, Lia MP, Israel A. Collaborative public-private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012-2016. J Healthc Leadersh. 2017;9:4 7-57. DOI: 10.2147/JHL.S130207.

Kostyanev T, Bonten MJ, O'Brien S, Steel H, Ross S, François B, Tacconelli E, et al.The innovative medicines initiative's new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother. 2016;71(2): 290-5. DOI: 10.1093/jac/dkv339.

Ustinova E.O. Public private partnership: experience of European Union countries. Materials of the scientific and practical conference “Public administration and local self-government: history and modernity”, Kharkiv; 2012. Ukrainian.

Batalov O.A., Valyushko I.V. Features of the use of public-private partnership as a mechanism for implementing a new regional policy. Analytical note. Available from: http://www.niss.gov.ua/articles/1239/. Ukrainian.

Ilyk R, Litovchenko I, Slobonichenko M, Pitel L, Korchakov-Khib N. Methodical recommendations for state and municipal health care institutions, for employees of health care management agencies for implementation of public-private partnership projects in health care field. [Методичні рекомендації для державних та комунальних закладів охорони здоров’я, для працівників органів управлiння у сфері охорони здоров’я для впровадження проектів державно-приватного партнерства у сфері охорони здоров’я] Kyiv; 2018. Available from: http://moz.gov.ua/uploads/1/7840-1234567890.pdf. Ukrainian.

Downloads

Published

2019-04-02

How to Cite

Litvinova, O. V., & Posilkina, O. V. (2019). PUBLIC-PRIVATE PARTNERSHIP IN THE IMPLEMENTATION OF INNOVATIVE PROJECTS ASSOCIATED WITH PHARMACEUTICAL DEVELOPMENTS FOR THE TREATMENT OF SOCIALLY SIGNIFICANT DISEASES. Pharmaceutical Review Farmacevtičnij časopis, (1), 79–87. https://doi.org/10.11603/2312-0967.2019.1.9931

Issue

No. 1 (2019)

Section

Pharmaceutical management, marketing and logistics

License

The authors who publish their materials in this journal agree with the following terms:

  • Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal Результат пошуку зображень за запитом "CC-BY logo".
  • Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.

Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).